Clinical trials: High Risk Prostate Cancer
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Prostate Cancer, High-risk Biochemical Recurrence
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
- Conditions
- Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT06555796
- Testing
- Xaluritamig
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Neoplasms, Prostate, Benign Prostatic Hyperplasia
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial.
- Conditions
- Neoplasms, Prostate, Benign Prostatic Hyperplasia, Cancer
- Trial name
- NCT01337258
- Testing
- Dutasteride
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Non-metastatic Castration-resistant Prostate Cancer
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that…
- Trial name
- NCT05348876
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 25 sites in India
- Volunteers
- 50 people
- Sponsor
- Bayer
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Prostate Cancer
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer.
- Trial name
- PRIORITI (NCT01753297)
- Testing
- Triptorelin 11.25 mg
- Where
- 18 sites in China, Russia
- Volunteers
- 226 people
- Sponsor
- Ipsen
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants…
- Trial name
- NCT04471727
- Testing
- Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
- Where
- 11 sites in United States
- Volunteers
- 232 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostatic Neoplasms
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT)…
- Trial name
- NCT02531516
- Testing
- Apalutamide, Bicalutamide, GnRH (agonist)
- Where
- 263 sites in United States, Argentina and 21 more
- Volunteers
- 1,503 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia)
Sonablate HIFU International Registry for PC & BPH Patients
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system.
- Conditions
- Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
- Trial name
- SONAFUSION (NCT07757490)
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Sonablate
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Prostate Cancer
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in…
- Trial name
- NCT00924469
- Testing
- Abiraterone, Leuprolide, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
This will be an open-labelled, single centre study in the UK. The study group will include 60 patients with three groups of patients being studied.
- Trial name
- PRONOUNCED (NCT03617588)
- Testing
- Gallium-68 THP-PSMA
- Where
- 4 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Theragnostics Ltd
Prostate Cancer
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma.
- Trial name
- NCT02805894
- Testing
- NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nanobiotix
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
- Trial name
- Solar-Stage (NCT06235151)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 43 sites in United States
- Volunteers
- 439 people
- Sponsor
- Curium US LLC
High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR)…
- Trial name
- NCT07875881
- Testing
- Deutenzalutamide Soft Capsules + ADT
- Where
- 3 sites in China
- Volunteers
- 1,044 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Prostate Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer.
- Trial name
- NCT00391690
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Novartis
High Risk Prostate Carcinoma
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by [18F]Florastamin PET/CT imaging examination to determine the presence of recurrent or…
- Trial name
- NCT05936658
- Testing
- [F-18]Florastamin
- Where
- 6 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- FutureChem
Prostate Cancer
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Radical prostatectomy is used to treat early prostate cancer in otherwise well men, but is followed by later cancer relapse in 1 in 4 cases.
- Trial name
- NCT00258765
- Testing
- Zoledronic Acid, Docetaxel
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Intraepithelial Neoplasia
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study.
- Trial name
- NCT00028353
- Testing
- GTX-006 (Acapodene)
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- GTx